British Journal of Cancer最新文献_第10页

Comment on: “A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures” 评论"乳腺癌患者接受乳房切除术后放疗后乳房重建的全国性研究：放疗分次和重建手术并发症比较

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-08-01 DOI: 10.1038/s41416-024-02807-3

Jilong Yuan, Ming Xiao, Qu Zheng

引用次数: 0

Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers 优化非胰腺周围癌的辅助治疗策略。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-07-31 DOI: 10.1038/s41416-024-02808-2

Nouredin Messaoudi, Aude Vanlander, Andrew A. Gumbs

引用次数: 0

Correction: Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer 更正：肿瘤细胞内在 PD-L1 信号诱导的上皮-间质转化可预测 PD-L1 高的肺癌患者对免疫检查点抑制剂的不良反应。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-07-30 DOI: 10.1038/s41416-024-02798-1

Hyein Jeong, Jaemoon Koh, Sehui Kim, Seung Geun Song, Soo Hyun Lee, Youngjoo Jeon, Chul-Hwan Lee, Bhumsuk Keam, Se-Hoon Lee, Doo Hyun Chung, Yoon Kyung Jeon

引用次数: 0

Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG) SIOP WT 2001 研究中同步双侧 Wilms 肿瘤的特征和预后：SIOP肾肿瘤研究小组（SIOP-RTSG）的报告。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-07-30 DOI: 10.1038/s41416-024-02799-0

Hélène Sudour-Bonnange, Harm van Tinteren, Gema L. Ramírez-Villar, Jan Godzinski, Sabine Irtan, Manfred Gessler, Tanzina Chowdhury, Georges Audry, Joerg Fuchs, Mark Powis, Cornelis P. van de Ven, Bruce Okoye, Naima Smeulders, Gordan M. Vujanic, Arnaud Verschuur, Aurore L’Herminé-Coulomb, Beatriz de Camargo, Joaquim Caetano de Aguirre Neto, Jens Peter Schenk, Mary M. van den Heuvel-Eibrink, Katy Pritchard-Jones, Norbert Graf, Christophe Bergeron, Rhoikos Furtwängler

{"title":"Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG)","authors":"Hélène Sudour-Bonnange, Harm van Tinteren, Gema L. Ramírez-Villar, Jan Godzinski, Sabine Irtan, Manfred Gessler, Tanzina Chowdhury, Georges Audry, Joerg Fuchs, Mark Powis, Cornelis P. van de Ven, Bruce Okoye, Naima Smeulders, Gordan M. Vujanic, Arnaud Verschuur, Aurore L’Herminé-Coulomb, Beatriz de Camargo, Joaquim Caetano de Aguirre Neto, Jens Peter Schenk, Mary M. van den Heuvel-Eibrink, Katy Pritchard-Jones, Norbert Graf, Christophe Bergeron, Rhoikos Furtwängler","doi":"10.1038/s41416-024-02799-0","DOIUrl":"10.1038/s41416-024-02799-0","url":null,"abstract":"Among patients with nephroblastoma, those with bilateral disease are a unique population where maximising tumour control must be balanced with preserving renal parenchyma. The SIOP 2001 protocol recommended surgery after neoadjuvant cycle(s) of Dactinomycin and Vincristine (AV) with response-adapted intensification, if needed. Adjuvant treatment was given based on the lesion with the worst histology. Three hundred and twenty seven patients with stage V disease were evaluable: 174 had bilateral Wilms tumour (BWT), 101 unilateral WT and contralateral nephroblastomatosis (NB) and 52 bilateral nephroblastomatosis. In these three groups, the estimated 5y-EFS was 76.1%, 84.6%, and 74.9%, respectively. AV chemotherapy alone was the successful chemotherapy for 58.7% of all the patients and 65.6% of the non-metastatic patients. Among the 174 patients with BWT, 149 (88.2%) had at least one nephron-sparing surgery. Twenty of 61 bilateral stage I patients were treated with four-week AV postoperatively achieving 94.4% 5y-EFS. At last follow-up, 87% of patients had normal renal function. This study demonstrates that AV without anthracyclines is sufficient to achieve NSS and good survival in the majority of patients. For patients with bilateral stage I WT and intermediate risk histology, only four weeks adjuvant AV seems to be sufficient. NCT00047138","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141854853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of opioid misuse in patients with cancer: a systematic review and meta-analysis 癌症患者滥用阿片类药物的普遍性：系统回顾和荟萃分析。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-07-26 DOI: 10.1038/s41416-024-02802-8

Tazha Ako, Mark Puch Ørnskov, Camilla Lykke, Per Sjøgren, Geana Paula Kurita

{"title":"Prevalence of opioid misuse in patients with cancer: a systematic review and meta-analysis","authors":"Tazha Ako, Mark Puch Ørnskov, Camilla Lykke, Per Sjøgren, Geana Paula Kurita","doi":"10.1038/s41416-024-02802-8","DOIUrl":"10.1038/s41416-024-02802-8","url":null,"abstract":"Long-term consequences of opioid consumption, such as misuse, have been a major concern in patients with chronic non-cancer pain. Potentially opioid misuse may also be a consequence in patients with cancer in opioid treatment which encouraged us to undertake this systematic review assessing the frequency of opioid misuse in this population. The search strategy comprised words related to cancer, opioid misuse, and frequency. PubMed, Embase, PsycInfo, and Cinahl were searched from inception to July 2023. Prospective studies were selected and analysed regarding frequency, study characteristics, and quality. A meta-analysis was possible to carry out for a sub-group (opioid misuse risk). From 585 abstracts screened, six articles were included. Only prevalence data were found. The prevalence of opioid misuse ranged from 5.7% to 84%, while the prevalence of opioid misuse risk varied from 2.4% to 35.4%. The pooled prevalence of opioid misuse risk was 12.3% (95% CI: 0.8–36.3; I2 = 98.4%, 95% CI: 97.2–99.1). The studies differed regarding, e.g., methods, misuse definitions, and assessment instruments. Few studies were identified and large differences in prevalence for opioid misuse and opioid misuse risk were observed. Methodological disparities and the studies quality underscore the importance of improved studies in the future.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02802-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer COLUMBIA-1：一项关于转移性微卫星稳定型结直肠癌中杜瓦单抗+奥利单抗联合化疗和贝伐单抗的随机研究。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-07-25 DOI: 10.1038/s41416-024-02796-3

Neil H. Segal, Jeanne Tie, Scott Kopetz, Michel Ducreux, Eric Chen, Rodrigo Dienstmann, Antoine Hollebecque, Matthew J. Reilley, Elena Elez, Jan Cosaert, Jason Cain, Yee Soo-Hoo, Nicola Hewson, Zachary A. Cooper, Rakesh Kumar, Josep Tabernero

{"title":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","authors":"Neil H. Segal, Jeanne Tie, Scott Kopetz, Michel Ducreux, Eric Chen, Rodrigo Dienstmann, Antoine Hollebecque, Matthew J. Reilley, Elena Elez, Jan Cosaert, Jason Cain, Yee Soo-Hoo, Nicola Hewson, Zachary A. Cooper, Rakesh Kumar, Josep Tabernero","doi":"10.1038/s41416-024-02796-3","DOIUrl":"10.1038/s41416-024-02796-3","url":null,"abstract":"To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab (anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti-tumour effect in patients with metastatic colorectal cancer (mCRC). COLUMBIA-1 (NCT04068610) was a Phase Ib (feasibility; Part 1)/Phase II (randomised; Part 2) trial in patients with treatment-naïve microsatellite stable mCRC. Patients in Part 2 were randomised to receive standard-of-care (control arm) or standard-of-care plus durvalumab and oleclumab (experimental arm). Primary objectives included safety and efficacy. Seven patients were enrolled in Part 1 and 52 in Part 2 (n = 26 in each arm). Grade ≥3 treatment-emergent adverse events (TEAE) occurred in 80.8% and 65.4% of patients in the control and experimental arms of Part 2, respectively, with 26.9% and 46.3% experiencing serious TEAEs. The confirmed objective response rate (ORR) was numerically higher in the experimental arm compared with the control arm (61.5% [95% confidence interval (CI), 40.6–79.8] vs 46.2% [95% CI, 26.6–66.6]) but did not meet the statistically significant threshold in either arm. The safety profile of FOLFOX and bevacizumab in combination with durvalumab and oleclumab was manageable; however, the efficacy results do not warrant further development of this combination in patients with microsatellite stable mCRC. NCT04068610.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02796-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland – a scoping review 更正：COVID-19 大流行对英国和爱尔兰共和国乳腺癌患者治疗途径和结果的影响--范围界定综述。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-07-25 DOI: 10.1038/s41416-024-02791-8

Lynne Lohfeld, Meenakshi Sharma, Damien Bennett, Anna Gavin, Sinéad T. Hawkins, Gareth Irwin, Helen Mitchell, Siobhan O’Neill, Charlene M. McShane

引用次数: 0

Unraveling the role of hepatitis B virus DNA integration in B-cell lymphomagenesis 揭示乙型肝炎病毒 DNA 整合在 B 细胞淋巴瘤形成中的作用。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-07-19 DOI: 10.1038/s41416-024-02763-y

Chieh-Lung Cheng, You-Yu Lin, Chia-Lang Hsu, Chiao-Ling Li, Chang-Tsu Yuan, Ya-Yun Lai, Wei-Quan Fang, Pei-Jer Chen, Shiou-Hwei Yeh, Hwei-Fang Tien

{"title":"Unraveling the role of hepatitis B virus DNA integration in B-cell lymphomagenesis","authors":"Chieh-Lung Cheng, You-Yu Lin, Chia-Lang Hsu, Chiao-Ling Li, Chang-Tsu Yuan, Ya-Yun Lai, Wei-Quan Fang, Pei-Jer Chen, Shiou-Hwei Yeh, Hwei-Fang Tien","doi":"10.1038/s41416-024-02763-y","DOIUrl":"10.1038/s41416-024-02763-y","url":null,"abstract":"Studies have shown that hepatitis B virus (HBV)-associated B-cell non-Hodgkin lymphoma (NHL) constitutes a unique subgroup with distinct clinical features. It still leaves open the question of whether the integration of HBV DNA into the B-cell genome is a causal mechanism in the development of lymphoma. Using the hybridisation capture-based next generation sequencing and RNA sequencing, we characterised the HBV integration pattern in 45 HBV-associated B-cell NHL tumour tissues. A total of 354 HBV integration sites were identified in 13 (28.9%) samples, indicating the relatively low integration frequency in B-cell NHLs. High plasma HBV DNA loads were not associated with the existence of HBV integration. The insertion sites distributed randomly across all the lymphoma genome without any preferential hotspot neither at the chromosomal level nor at the genetic level. Intriguingly, most HBV integrations were nonclonal in B-cell NHLs, implying that they did not confer a survival advantage. Analysis of the paired diagnosis-relapse samples showed the unstable status of HBV integrations during disease progression. Furthermore, transcriptomic analysis revealed the limited biological impact of HBV integration. Our study provides an unbiased HBV integration map in B-cell NHLs, revealing the insignificant role of HBV DNA integration in B-cell lymphomagenesis.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Associations of diabetes and mortality among colorectal cancer patients from the Southern Community Cohort Study 南方社区队列研究》中结直肠癌患者的糖尿病与死亡率之间的关系。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-07-19 DOI: 10.1038/s41416-024-02787-4

Thomas Lawler, Elizabeth Hibler, Zoe L. Walts, Lauren Giurini, Mark Steinwandel, Loren Lipworth, Harvey J. Murff, Wei Zheng, Shaneda Warren Andersen

{"title":"Associations of diabetes and mortality among colorectal cancer patients from the Southern Community Cohort Study","authors":"Thomas Lawler, Elizabeth Hibler, Zoe L. Walts, Lauren Giurini, Mark Steinwandel, Loren Lipworth, Harvey J. Murff, Wei Zheng, Shaneda Warren Andersen","doi":"10.1038/s41416-024-02787-4","DOIUrl":"10.1038/s41416-024-02787-4","url":null,"abstract":"We investigated associations between diabetes and mortality among participants with incident colorectal cancer (CRC) from the Southern Community Cohort Study. Participants (73% non-Hispanic Black; 60% income < $15,000) were recruited between 2002–2009. Diabetes was self-reported at enrollment and follow-up surveys at approximately 5-year intervals. Incident CRC and mortality were identified via state registries and the National Death Index. Proportional hazards models calculated associations between diabetes with overall, CRC-specific mortality among 1059 participants with incident CRC. Diabetes prior to diagnosis is associated with elevated overall (hazard ratio [95% confidence interval]: (1.46[1.22–1.75]), and CRC-specific mortality (1.36[1.06–1.74])) after adjustment for tumor stage. For non-Hispanic Black and non-Hispanic White participants, consistent associations were observed for overall (1.35[1.10–1.66] vs. 1.89[1.31–2.72], respectively, p-interaction = 0.11) and CRC-specific mortality (1.30[0.99–1.71] vs. 1.77[1.06–2.95], respectively, p-interaction = 0.28). For individuals with incomes <$15,000/year, associations with overall (1.44[1.15–1.79]) and CRC-specific mortality (1.28[0.94–1.73]) were similar to the full sample. Associations with overall (1.71[1.37–2.13]) and CRC-specific mortality (1.65[1.22–2.22]) were highest for diabetes ≥ 10 years at diagnosis. Pre-diagnosis diabetes is associated with higher mortality among participants with incident CRC from a predominantly non-Hispanic Black cohort with lower socioeconomic status. The higher prevalence of diabetes in this population may contribute to racial disparities in CRC mortality.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141726912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium 诊断前饮用茶和咖啡与卵巢癌诊断后的存活率：卵巢癌协会联合会的研究结果。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-07-18 DOI: 10.1038/s41416-024-02792-7

Christina M. Nagle, Torukiri I. Ibiebele, Elisa V. Bandera, Daniel Cramer, Jennifer A. Doherty, Graham G. Giles, Marc T. Goodman, Gillian E. Hanley, Holly R. Harris, Allan Jensen, Susanne K. Kjaer, Alice W. Lee, Roger L. Milne, Bo Qin, Jean Richardson, Naoko Sasamoto, Weiva Sieh, Kathryn L. Terry, Linda Titus, Britton Trabert, Nicolas Wentzensen, Anna H. Wu, Andrew Berchuck, Malcolm Pike, Celeste Leigh Pearce, Penelope M. Webb

{"title":"Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium","authors":"Christina M. Nagle, Torukiri I. Ibiebele, Elisa V. Bandera, Daniel Cramer, Jennifer A. Doherty, Graham G. Giles, Marc T. Goodman, Gillian E. Hanley, Holly R. Harris, Allan Jensen, Susanne K. Kjaer, Alice W. Lee, Roger L. Milne, Bo Qin, Jean Richardson, Naoko Sasamoto, Weiva Sieh, Kathryn L. Terry, Linda Titus, Britton Trabert, Nicolas Wentzensen, Anna H. Wu, Andrew Berchuck, Malcolm Pike, Celeste Leigh Pearce, Penelope M. Webb","doi":"10.1038/s41416-024-02792-7","DOIUrl":"10.1038/s41416-024-02792-7","url":null,"abstract":"Tea and coffee are the most frequently consumed beverages in the world. Green tea in particular contains compounds with potential anti-cancer effects, but its association with survival after ovarian cancer is uncertain. We investigated the associations between tea and coffee consumption before diagnosis and survival using data from 10 studies in the Ovarian Cancer Association Consortium. Data on tea (green, black, herbal), coffee and caffeine intake were available for up to 5724 women. We used Cox proportional hazards regression to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Compared with women who did not drink any green tea, consumption of one or more cups/day was associated with better overall survival (aHR = 0.84, 95% CI 0.71–1.00, p-trend = 0.04). A similar association was seen for ovarian cancer-specific survival in five studies with this information (aHR = 0.81, 0.66–0.99, p-trend = 0.045). There was no consistent variation between subgroups defined by clinical or lifestyle characteristics and adjustment for other aspects of lifestyle did not appreciably alter the estimates. We found no evidence of an association between coffee, black or herbal tea, or caffeine intake and survival. The observed association with green tea consumption before diagnosis raises the possibility that consumption after diagnosis might improve patient outcomes.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02792-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0